    Andrew Ritter | Ritter Pharmaceuticals Inc | ZoomInfo.com

Ritter Pharmaceuticals, Lactose Intolerance Experts, Pharma Biotech Experience | Ritter Pharmaceuticals




































 







      Ritter Pharmaceuticals      |
      Therapeutic Treatments for Gastrointestinal Diseases      


CareersContact
Connect with us   





Home
About Us

History


Leadership

Overview
Leadership Team
Medical Advisory Board
Board of Directors


Lactose Intolerance

Overview
Health Consequences
Standard of Care
Market Opportunity
Patient Resources


Microbiome Modulation
Investors

Overview
Events & Presentations
Corporate Governance
SEC Filings & Stock Info
Investor FAQs
Contact Us


News

Press Releases / News
Blog


Contact Us

Contact Us
Careers


Lactagen
RP-G28
Product Pipeline
















 Print This Page







Leadership Team
Ritter Pharma has recruited and assembled an outstanding team of talented and experienced individuals with extensive big pharma & biotech experience.
Michael D. Step
Chief Executive Officer
Prior to joining Ritter, Mr. Step was the Senior Vice President of Corporate Development for Santarus, Inc., now a wholly owned subsidiary of Salix Pharmaceuticals, Inc. Mr. Step served in this role for nine years up until the 2014 sale of Santarus to Salix. Mr. Step was responsible for leading all licensing and M&A activities at Santarus and was a member of its executive team. Prior to his tenure at Santarus, Mr. Step held various commercial and business development roles at Amylin Pharmaceuticals for 5 years, culminating in the role of Vice President of Corporate Development and was responsible for leading Amylin’s license of Byetta to Eli Lilly. Before joining Amylin, Mr. Step was Sr. Director of Business Development at Dura Pharmaceuticals and served in licensing, management and sales roles at Hoffmann-La Roche and Syntex Labs. Mr. Step has an MBA degree in marketing and finance from the USC Marshall School of Business and an undergraduate degree from Vanderbilt University.

Andrew J. Ritter
Co-Founder & President
Mr. Ritter co-founded Ritter Pharmaceuticals, Inc., upon his own personal affliction with lactose intolerance and spearheaded a global team of cross-functional, clinical, manufacturing, and regulatory experts to design and develop its first novel therapeutic called, RP-G28. This product has been successfully tested in a Phase 2a trial and has the potential to become the first FDA-approved drug for the treatment of lactose intolerance. The company was originally launched out of Ritter Naturals Sciences, a direct-to-consumer healthcare marketing company, founded by Mr. Ritter in 2004, which developed and commercialized digestive healthcare products: Lactagen®, Health Essentials™ and Better Digestion™. Mr. Ritter holds six patents and over fifteen additional international patents are pending. In addition, he has co-published articles in the following journals: Nutrition Journal, Gastroenterology, and Food Technology. He has also given presentations at major healthcare and medical conferences such as Digestive Disease Week, among others.
Since 2010, Mr. Ritter has also acted as Managing Partner of Stonehenge Partners, a private investment fund, which provides working capital and executive leadership to a variety of businesses and industries including, real estate, technology, biotechnology, entertainment and service businesses. In addition, he is a guest lecturer of entrepreneurship at various graduate and undergraduate academic institutions throughout Los Angeles including: University of Southern California Marshall School of Business, University of California at Los Angeles Anderson School of Business, and Pepperdine University Graziadio School of Business and Management.
Mr. Ritter has been an active leader in his community, including being appointed as a Los Angeles City Commissioner to the Commission for Children, Youth and Their Families from 2000-2002 (the youngest appointed Commissioner in Los Angeles history). Mr. Ritter holds a Bachelor of Arts Degree in Political Science and a minor in Business from the University of Southern California and was a member of the 2002 Pac-10 Champion baseball team. In addition, Mr. Ritter received his MBA from The Wharton School, University of Pennsylvania.
Ira E. Ritter
Co-Founder & Chief Strategic Officer
Mr. Ritter has extensive experience creating, building and managing diverse business enterprises. His success has been his ability to take ideas and grow major businesses. He currently serves as Chairman of Ritter Pharmaceuticals. In addition he provides corporate management, strategic planning and financial consulting for a wide range of market segments. In the health and beauty sector, Mr. Ritter was President and Vice-Chairman of Quality King Inc, the nation’s largest wholesale distributor for health care products with $5 billion in annual revenues (ranked the 18th largest privately held company, Forbes Top 100 List). Simultaneously, he worked as President and Chairman of Rockwood, a business he developed that produced private label HBA products for major national retailers including GNC and K-Mart. In the entertainment sector he served as Chairman of ON-TV, a division of Oak Industries (NYSE Company), where he managed the television division initiating exclusive broadcasts of Los Angeles, Chicago, and New York professional baseball, basketball, and hockey games. During 1980-1985, he produced the first televised home shopping program and directed development of the largest “pay-per-view” channel system for its time. In the personal services market, Mr. Ritter grew a people-to-people business, Elite Personal Search and Lifemates personal matchmaking service, in the U.S. and Canada. In the finance field, Mr Ritter served on the board of directors for the Martin Lawrence Art Galleries (NYSE Company). During his 20 years as a publisher, he produced monthly national consumer magazines including Playgirl. and released books that included It’s OK to Say No children's series and Patti Regan Davis’ Homefront. Mr. Ritter also has a long history of public service that includes appointments by three Governors to several State of California Commissions, including eight years served as Commissioner on the California Prison Industry Authority. In 1981, Mr. Ritter was honored with the City of Hope’s Man of the Year award.

Ellen Mochizuki
Vice President, Finance
Ms. Mochizuki has over 25 years of experience in financial accounting. Prior to joining Ritter Pharmaceuticals, Inc., Ms. Mochizuki consulted with various biopharmaceutical clients with respect to their initial public offerings and related financial statements, as well as assisting with a stock merger for a publicly traded mid-size banking client. From 2007 to 2014, Ms. Mochizuki served as Director of Accounting (Benefits) for Northrop Grumman Corporation (NGC) where she was responsible for the overall accounting and accounting operations of its benefit assets of over $50 billion, including the filing of over twenty external financial statements annually. From 2006 to 2007, Ms. Mochizuki was a consultant for NGC. From 2002 to 2005, Ms. Mochizuki was Senior Vice President at IndyMacBank, where she oversaw human resources operations. Ms. Mochizuki started her career as an auditor with PricewaterouseCoopers, LLP. In addition, Ms. Mochizuki is an adjunct faculty at Pasadena City College teaching accounting (2014-Present). Ms. Mochizuki is licensed in the State of California as a certified public accountant, though is currently on inactive status. 













Leadership

Board of Directors
Leadership Team
Medical Advisory Board
Overview


























 








Home  |  About Us  |  Investors  |  Therapies  |  Platform  |  Leadership  |  Lactose Intolerance  |  News  |   Contact Us  |  Privacy Policy  |  Terms & Conditions  |  Site Map
    © Copyright 2017 Ritter Pharmaceuticals. All Rights Reserved






Featuring Recent Posts WordPress Widget development by YD








Andrew J Ritter - Holliston, MA | Intelius



























Sign In



We found Andrew J Ritter in Holliston, MA


Andrew J Ritter

                                                                           Intelius found that Andrew J Ritter  is  a male between 60 and 70 years old from Holliston, MA.  We have connected them to
                5 addresses,
                2 phones,
                and 4 relatives or associates.
         





Also Known As

Andy J Ritter


Get Report Now

Age

Andrew J Ritter is in his 60s

Andrew Has Lived In

Holliston, MA
Boston, MA
Natick, MA

Andrew's Relatives

Kathleen Ritter
Lawrence Ritter
Barbara Ritter
Michael Ritter







Andrew J Ritter



Zodiac SignGemini



GenderMale



Professional Status
Suffolk University



Get Report Now










Want to know more about Andrew? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Andrew, or use our people search engine to find others.
Get Background Check on Andrew J Ritter
Get a Criminal Check on Andrew J Ritter
Get a Public Record Report on Andrew J Ritter
Get a People Search Report on Andrew J Ritter


Andrew J Ritter's Contact Information
Known Cities Lived In
Find out where Andrew J Ritter has lived as well as Andrew J Ritter's phone numbers and email addresses.




Andrew J Ritter Has Lived in 1 States
Massachusetts Address for Andrew J Ritter


161 D*** D* 

Holliston, MA


Has Lived In

Holliston, MA
Boston, MA


Get Full Address Report










Phone Numbers Associated with Andrew J Ritter

(508) ***-**** - Holliston, MA 
(508) ***-**** - Holliston, MA 


Get Full Phone Report



Email Addresses Associated with Andrew J Ritter

a********a@***.com
a******r@***.edu


Get Email Report




Andrew J Ritter's Professional Information
Information regarding Andrew J Ritter's professional history.  Find out previous places Andrew J Ritter has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Andrew J Ritter Has Worked at 1 Place
Company: Suffolk University
               
Andrew J Ritter's Experience
Title: 
               Company: Suffolk University
Job Details
               Suffolk University, located on Boston's historic Beacon Hill, with campuses in Madrid and Dakar, Senegal (Africa), is a comprehensive global institution distinguished by its teaching and the intellectual contributions of its faculty. Suffolk offers a wide range of undergraduate and graduate programs in more than 70 areas of study. Its mission is to provide quality education at a reasonable cost for students of all ages and backgrounds, with strong emphasis on diversity.
Additional Professional Information on Andrew J Ritter

 See Andrew J Ritter's LinkedIn Profile



Andrew J Ritter's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Andrew J Ritter


Andrew J Ritter's known Social Networks And Potential Email Matches

Find all of Andrew J Ritter's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Andrew Ritter
Username Matches

                  AndrewRitter
                  RitterAndrew
                  Andrew.Ritter
                  Ritter.Andrew
                  Andrew_Ritter
                  Ritter_Andrew
                  Andrew-Ritter
                  Ritter-Andrew
                  ARitter
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
A Ritter







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.













Andrew J. Ritter: Executive Profile & Biography - Bloomberg









































  





















































































July 28, 2017 10:02 AM ET
Pharmaceuticals

Company Overview of Ritter Pharmaceuticals, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Andrew J. Ritter  Co-Founder, President, Corporate Secretary & Director, Ritter Pharmaceuticals, Inc.AgeTotal Calculated CompensationThis person is connected to 1 Board Members in 1 different organizations across 1 different industries.See Board Relationships34$931,584As of Fiscal Year 2016
Background

		Mr. Andrew J. Ritter Co-founded Ritter Pharmaceuticals, Inc in March 2008 and has been  the President of Ritter Pharmaceuticals, Inc., since  2008. Mr. Ritter. Mr. Ritter served as Chief Executive Officer of Ritter Pharmaceuticals, Inc until October 2014. He has been actively studying the field of lactose intolerance for over 15 years. Since 2010, he has also acted as Managing Partner of Stonehenge Partners, a private investment fund which provides working capital and ... executive leadership to a variety of businesses and industries. Those industries include: Real Estate, Tech, Biotech, Entertainment and Service businesses. He serves as  Secretary at Ritter Pharmaceuticals, Inc. He has been a Director at Ritter Pharmaceuticals, Inc. since 2008. He is a Guest Lecturer of entrepreneurship at various graduate and undergraduate schools throughout Los Angeles including: Marshall School of Business, University of Southern California, Anderson School of Business, University of California of Los Angeles and Pepperdine University Graziadio School of Business and Management. Los Angeles Mayor, Richard Riordan, appointed Mr. Ritter to serve as a Los Angeles City Commissioner from 2000 to 2002 (The youngest appointed Commissioner in Los Angeles history.). He was a Member of the 2002 Pac-10 Champion baseball team. Mr. Ritter holds a Bachelor Degree in Political Science and a minor in Business from the University of Southern California. He graduated from the Stanford Graduate School of Business’ Executive Education on Influence and Negotiation Strategies.Read Full Background




Corporate Headquarters
1880 Century Park EastLos Angeles, California 90067United StatesPhone: 310-203-1000Fax: 310-919-1600
Board Members Memberships
2008-PresentCo-Founder, President, Corporate Secretary & DirectorRitter Pharmaceuticals, Inc.
Education
Bachelor's Degree University of Southern CaliforniaMBA 2016University of Pennsylvania - The Wharton SchoolUnknown/Other Education Stanford Graduate School of Business
Other Affiliations
University of Southern CaliforniaUniversity of Pennsylvania - The Wharton SchoolStanford Graduate School of Business


Annual Compensation
Salary$324,010Bonus$117,180Total Annual Compensation$441,190
Stocks Options
Exercisable Options$292,341Unexercisable Options$411,089Total Number of Options$703,430
Total Compensation
Total Annual Cash Compensation$441,190Total Short Term Compensation$441,190Total Calculated Compensation$931,584




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Ritter Pharmaceuticals, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close




























Ritter Pharmaceuticals, Leading Lactose Intolerance Researchers | Ritter Pharmaceuticals





































 







      Ritter Pharmaceuticals      |
      Therapeutic Treatments for Gastrointestinal Diseases      


CareersContact
Connect with us   





Home
About Us

History


Leadership

Overview
Leadership Team
Medical Advisory Board
Board of Directors


Lactose Intolerance

Overview
Health Consequences
Standard of Care
Market Opportunity
Patient Resources


Microbiome Modulation
Investors

Overview
Events & Presentations
Corporate Governance
SEC Filings & Stock Info
Investor FAQs
Contact Us


News

Press Releases / News
Blog


Contact Us

Contact Us
Careers


Lactagen
RP-G28
Product Pipeline
















 Print This Page







Leadership
We are committed to developing cutting-edge treatments for gastrointestinal diseases. Our management team, with years of relevant clinical, regulatory and commercial experience, is supported by an outstanding medical advisory board comprised of foremost researchers in lactose intolerance and gastrointestinal diseases.
Together we are committed to the vision of reducing the debilitating impact of lactose intolerance on patients globally.















Leadership

Board of Directors
Leadership Team
Medical Advisory Board
Overview


























 








Home  |  About Us  |  Investors  |  Therapies  |  Platform  |  Leadership  |  Lactose Intolerance  |  News  |   Contact Us  |  Privacy Policy  |  Terms & Conditions  |  Site Map
    © Copyright 2017 Ritter Pharmaceuticals. All Rights Reserved






Featuring Recent Posts WordPress Widget development by YD











Ritter, Andrew J. - The Wall Street Transcript











































 





































Andrew J. Ritter
Andrew J. Ritter, Co-Founder and President, co-founded Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) upon his own personal affliction with lactose intolerance, and spearheaded a global team of cross-functional, clinical, manufacturing and regulatory experts to design and develop its first novel therapeutic, called RP-G28. The company was originally launched out of Ritter Naturals Sciences, a direct-to-consumer health care marketing company founded by Mr. Ritter in 2004, which developed and commercialized digestive health care products Lactagen, Health Essentials and Better Digestion. Mr. Ritter holds six patents, and over 15 additional international patents are pending. He has co-published articles in Nutrition Journal, Gastroenterology and Food Technology, and has given presentations at major health care and medical conferences such as Digestive Disease Week, among others. Since 2010, Mr. Ritter has also acted as Managing Partner of Stonehenge Partners, a private investment fund, which provides working capital and executive leadership to a variety of businesses and industries, including real estate, technology, biotechnology, entertainment and service businesses. In addition, he is a guest lecturer of entrepreneurship at various graduate and undergraduate academic institutions throughout Los Angeles, including University of Southern California Marshall School of Business, University of California at Los Angeles Anderson School of Business, and Pepperdine University Graziadio School of Business and Management. Mr. Ritter has been an active leader in his community, including being appointed as a Los Angeles City Commissioner to the Commission for Children, Youth and Their Families from 2000 to 2002 — the youngest appointed Commissioner in Los Angeles history. He holds a B.A. in political science and a minor in business from the University of Southern California, and was a member of the 2002 Pac-10 Champion baseball team. Mr. Ritter received his MBA from The Wharton School, University of Pennsylvania.
Related Interviews:Interview with the Co-Founder and President and the CEO: Ritter Pharmaceuticals Inc. (NASDAQ:RTTR)July 01, 2016







CartLatest NewsAll American USC Footbal Player Joseph M. Boskovich Jr. Now Picks All American Value Stocks for his ClientsPaul Hogan Picks Tech Dividend Growers Microchip Technology (NASDAQ:MCHP), Xilinx (NASDAQ:XLNX) and Versum Materials (NYSE:VSM)600 Gallons of Water to Produce a McDonalds (NYSE:MCD) Quarter Pounder:  How Will Investors Profit?The Wall Street Transcript is a completely unique resource for investors and business researchers.Over 20,000 CEO, Equity Analyst and Money Manager InterviewsSubscribe now!Sign Up For Newsletter Weekly email with New In-Depth Interviews


Email: 



Most Popular InterviewsBuilding Diversified Portfolios with Quality Global EquitiesGregory D. PadillaAlberto Jimenez Crespo Published July 27, 2017 in Investing StrategiesCompanies covered: AMZN 005930 AAPL MU WHR KIMBERA GS VOD PPG SHW VIV PEY Buy ($25)Building Accountability and Avoiding Mistakes Through the Decision ProcessDean  Pagonis Published July 27, 2017 in Investing StrategiesCompanies covered: CMP SBH AMZN ULTA CVS LRLCY KMB WWW SDF Buy ($25)Finding Optimal Balance Sheets by Utilizing High Yield Market ExpertiseZach  Miller Published July 27, 2017 in Investing StrategiesCompanies covered: LSXMK SIRI BLL CHTR ARMK Buy ($25)Most Popular ReportsInvesting Strategies Published July 24, 2017Buy ($175)Wireless Communications & Telecom Published July 14, 2017Buy ($175)Investing Strategies Published July 11, 2017Buy ($175) 






Top Company Interviews






Register for a Free Account to gain greater access to
            The Wall Street Transcript right now




CEO INTERVIEWSInterview with the President and CEO: Lumos Networks Corp. (NASDAQ:LMOS)Interview with the Corporate VP of Business Development, Strategy and Investor Relations: DSP Group, Inc. (NASDAQ:DSPG)Interview with the CEO and Director: Tactile Systems Technology, Inc. (NASDAQ:TCMD) 

SECTOR ROUNDTABLESNatural Gas Weighs Heavy On E&P Near-Term ProspectsRoundtable Forum:optimism Despite Uncertainty In For-profit EducationRoundtable Forum:a Shift In Focus To Natural Gas From Oil 

MONEY MANAGER INTERVIEWSBuilding Diversified Portfolios with Quality Global EquitiesBuilding Accountability and Avoiding Mistakes Through the Decision ProcessFinding Optimal Balance Sheets by Utilizing High Yield Market Expertise 

ANALYST INTERVIEWSAnalyzing the Secular Drivers Within Communications Infrastructure and TelecomSatellite Companies Benefiting from Growth in Data TrafficIncreased Focus on Content as Consumers Shift to Digital Consumption 




Subscribe Today!







                Since 1963
                © The Wall Street Transcript 1997-2016
Terms and Conditions
Privacy Policy  
            





https://www.twst.com/wp-admin/admin-ajax.php

Pin It on Pinterest





































Share This





Twitter





Facebook





Google+





Gmail





LinkedIn








































×





Join now for free!
Already a member?






First Name 





Last Name 





Email address *








Create new account
 


or create an account with a social network.

Join with Facebook


Join with Twitter


Join with Google








Username or Email address: *





Password: *






LoginJoin now! | Forgot password?
 


or login using a social network


Log in with Facebook


Log in with Twitter


Log in with Google












Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business UpdateHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreTry Yahoo Finance on Firefox »YahooSearchSearchSign inU.S. Markets close in 5 hrs 57 minsS&P 5002,468.75-6.67 (-0.27%)Dow 3021,772.37-24.18 (-0.11%)Nasdaq6,358.61-23.58 (-0.37%)Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business UpdateMarketwiredFebruary 27, 2017ReblogShareTweetShareLOS ANGELES, CA--(Marketwired - Feb 27, 2017) - Ritter Pharmaceuticals, Inc. (  NASDAQ :  RTTR ) ("Ritter Pharmaceuticals" or the "Company"), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results for the fourth quarter and full year ended December 31, 2016.Recent HighlightsLast patient dosing and all monitoring visits of the Company's Phase 2b/3, 377 subject clinical trial of lead product candidate, RP-G28, for the treatment of lactose intolerance was completed on schedule in October 2016; Initiated a 12-month extension study to evaluate the long-term durability of RP-G28 on a subset of Phase 2b/3 clinical trial patients in October 2016; Presented at the 4th Microbiome R&D Business Collaboration Forum in October 2016; Raised gross proceeds of approximately $5 million, in an underwritten public offering in October 2016 to support operations and other general corporate purposes; CNBC Article published: "A Race to Turn Trillions of Our Own Bacterial into Medical Breakthroughs," by Andrew Ritter was published in November 2016; Presented at the 9th Annual LD Micro Main Event in December 2016; Clinical microbiome data from the Company's Phase 2a clinical trial of RP-G28 in patients with lactose intolerance was published in the Proceedings of the National Academy of Science in January 2017; Appointed William Merino, Ph.D., to the Company's Board of Directors in January 2017; Rang the closing bell at NASDAQ in January 2017; Established a partnership with the University of Nebraska and Dr. Amanda Ramer-Tait to study the role of the microbiome and RP-G28 in metabolic syndrome in January 2017; and Established a partnership with Dr. B Brett Finlay from the Michael Smith Laboratories at the University of British Columbia to study the role of the microbiome and RP-G28 in environmental enteropathy."2016 was a significant year for Ritter Pharmaceuticals as we were able to successfully initiate and complete our Phase 2b/3 clinical trial in less than 8-months, hitting our target completion date and putting us in a position for anticipated data readout in the first quarter of 2017," said Michael D. Step, Chief Executive Officer of Ritter Pharmaceuticals.Andrew J. Ritter, President of Ritter Pharmaceuticals, added, "This year, we look forward to advancing RP-G28 into Phase 3 as we near one step closer to developing RP-G28 as the first FDA approved treatment for lactose intolerance, while we also continue to look at expanding our product development efforts in additional indications."Fourth Quarter and Full Year 2016 Financial ResultsFor the fourth quarter of 2016, Ritter Pharmaceuticals reported a net loss attributable to common stockholders of approximately $7.6 million compared to a net loss of approximately $2.2 million for the fourth quarter of 2015. Basic and diluted net loss per share was $0.74 for the three months ended December 31, 2016 compared to basic and diluted net loss per share of $0.27 for the same period in 2015.For the year ended December 31, 2016, Ritter Pharmaceuticals reported a net loss attributable to common stockholders of approximately $18.4 million compared to a net loss of approximately $9.2 million for the year ended December 31, 2015. Basic and diluted net loss per share was approximately $2.04 for the year ended December 31, 2016 compared to basic and diluted net loss per share of approximately $3.11 for the same period in 2015.Research and development expenses for the fourth quarter of 2016 totaled approximately $6.2 million compared to approximately $676,000 for the fourth quarter of 2015. This increase was due to the Phase 2b/3 clinical trial.For the year ended December 31, 2016, research and development expenses totaled approximately $13.3 million compared to approximately $2.3 million for the year ended December 31, 2015. The increase in research and development expenses was attributable to the Phase 2b/3 clinical study in 2016.General and administrative expenses for the fourth quarter of 2016 were approximately $1.3 million, compared to approximately $1.5 million for the fourth quarter of 2015.For the year ended December 31, 2016, general and administrative expenses were approximately $4.9 million, compared to approximately $6.4 million for the year ended December 31, 2015. The decrease in general and administrative expenses was primarily due to lower stock based compensation expenses and continued cost containment measures.For the year ended December 31, 2016, total operating expenses were $18.4 million, compared to approximately $8.9 million for the year ended December 31, 2015.As of December 31, 2016, Ritter Pharmaceuticals had cash and cash equivalents of approximately $7.0 million.About Ritter Pharmaceuticals Ritter Pharmaceuticals, Inc. (www.RitterPharma.com, @RitterPharma) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic, and liver disease.Forward-Looking StatementsThis release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to our ability to bring RP-G28 to market. Management believes that these forward-looking statements are reasonable as and when made. However, such statements involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the drug development process generally, including the outcomes of planned clinical trials and the regulatory review process. For a discussion of certain risks and uncertainties affecting Ritter Pharmaceuticals' forward-looking statements, please review the Company's reports filed with the Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Ritter Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.      RITTER PHARMACEUTICALS, INC.   STATEMENTS OF OPERATIONS           Three Months Ended December 31,     Year Ended  December 31,         2016     2015     2016     2015         (unaudited)           Operating costs and expenses:                                     Research and development   $ 6,180,311     $ 676,211     $ 13,292,488     $ 2,260,297       Patent costs     72,626       83,430       272,514       243,463       General and administrative     1,348,117       1,543,967       4,881,725       6,404,643         Total operating costs and expenses     7,601,054       2,303,608       18,446,727       8,908,403     Operating loss     (7,601,054 )     (2,303,608 )     (18,446,727 )     (8,908,403 )                                       Other income:                                     Interest income     10,413       17,719       60,879       40,876       Other income     --       63,074       1,214       79,756         Total other income     10,413       80,793       62,093       120,632     Net loss   $ (7,590,641 )   $ (2,222,815 )   $ (18,384,634 )   $ (8,787,771 )                                       Cumulative preferred stock dividends     --       --       --       (327,569 )   Accretion of discount on Series C preferred stock     --       --       --       (63,283 )   Net loss applicable to common shareholders   $ (7,590,641 )   $ (2,222,815 )   $ (18,384,634 )   $ (9,178,623 )                                       Net loss per common share ― basic and diluted   $ (0.74 )   $ (0.27 )   $ (2.04 )   $ (3.11 )                                       Weighted-average common shares outstanding -- basic and diluted     10,219,941       8,095,593       8,993,317       2,946,792                                              RITTER PHARMACEUTICALS, INC.   BALANCE SHEETS         December 31, 2016     December 31, 2015                       ASSETS                 Current assets                   Cash and cash equivalents $ 7,046,282     $ 15,819,566       Prepaid expenses   156,752       189,136         Total current assets   7,203,034       16,008,702                       Other assets   10,326       10,326     Property and equipment, net   23,542       20,688         Total Assets $ 7,236,902     $ 16,039,716                       LIABILITIES AND STOCKHOLDERS' EQUITY                 Current liabilities                   Accounts payable $ 1,896,368     $ 739,357       Accrued expenses   1,222,735       614,141       Other liabilities   14,736       1,223         Total current liabilities   3,133,839       1,354,721                       Stockholders' equity                 Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding   --       --     Common stock, $0.001 par value; 25,000,000 shares authorized; 11,619,197 and 8,582,004 shares issued and outstanding as of December 31, 2016 and December 31, 2015, respectively   11,619       8,582     Additional paid-in capital   49,559,020       41,759,355     Accumulated deficit   (45,467,576 )     (27,082,942 )       Total stockholders' equity   4,103,063       14,684,995                           Total Liabilities and Stockholders' Equity $ 7,236,902     $ 16,039,716    ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextVerizon soars on beat, Starbucks' big China deal, AstraZeneca sinks as drug trial disappointsYahoo FinanceEngineer Finds Pattern; Makes Millions in StocksMoney MorningSponsoredShares in AstraZeneca dive as key cancer drug trial failsAssociated PressPascal Soriot 'here today' after bad trial results wipe £10bn from AstraZeneca valueThe TelegraphThe Next AIDS PandemicForeign Policy MagazineTrunk Club. Making Sense of Style.Trunk ClubSponsoredHas Glioblastoma Met Its Match In John McCain?International Business TimesTrump’s unwitting legacy could be universal health coverageYahoo FinanceSean Hannity responds to claim he ran up a $42,000 tab at Trump's hotel after flying in a 70-year-old lobster from MaineBusiness InsiderDiscover it: 4.8 out of 5 avg. by 24K+ customersDiscover CardSponsoredU.S. economic growth picks up in second quarter, wages continue to lagReutersTwitter is only famous now because of President Trump: NYSE traderYahoo Finance VideoInvestors yawn as US economic growth rebounds in the second quarter; Amazon fallsYahoo Finance"Women Need To Carry This Device With Them"Siren SongSponsoredIs a Surprise Coming for Apple (AAPL) This Earnings Season?ZacksWall Street opens lower as Amazon weighs on tech stocksReutersU.S. Would 'Utterly Destroy' North Korea Military, Says Top Army OfficialRyan: Yes we could do what he said, but not before North korea Utterly destoryed Seoul killing hundreds of thousands. That's not even considering if they use a nuke.Join the Conversation1 / 5253








Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business UpdatesHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreTry Yahoo Finance on Firefox »YahooSearchSearchSign inU.S. Markets close in 5 hrs 58 minsS&P 5002,468.74-6.68 (-0.27%)Dow 3021,772.24-24.31 (-0.11%)Nasdaq6,358.39-23.80 (-0.37%)Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business UpdatesMarketwiredMay 9, 2017ReblogShareTweetShareLOS ANGELES, CA--(Marketwired - May 9, 2017) - Ritter Pharmaceuticals, Inc. (  NASDAQ :  RTTR ) ("Ritter Pharmaceuticals" or the "Company"), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results for the first quarter ended March 31, 2017 and provided other business updates.Recent HighlightsClinical microbiome data from the Company's Phase 2a clinical trial of RP-G28 in patients with lactose intolerance was published in the Proceedings of the National Academy of Science; Appointed William Merino, Ph.D., to the Company's Board of Directors; Rang the closing bell at NASDAQ; Established a partnership with the University of Nebraska and Dr. Amanda Ramer-Tait to study the role of the microbiome and RP-G28 in metabolic syndrome; Established a partnership with Dr. B. Brett Finlay from the Michael Smith Laboratories at the University of British Columbia to study the role of the microbiome and RP-G28 in environmental enteropathy; Announced top-line data from our Phase 2b/3 clinical trial of RP-G28 in patients with lactose intolerance; Announced the issuance of three new patents, two in the U.S. and one in Australia, directed toward compositions containing and methods of using RP-G28; and Established a new equity facility with Aspire Capital Fund, LLC on May 4, 2017, to give the Company the flexibility and capability to access up to $6.5 million in equity capital in the future at the Company's sole discretion. "The key event of the quarter was our announcement of top-line data from our Phase 2b/3 clinical trial of RP-G28 in patients with lactose intolerance. Results from the trial demonstrated a clinically meaningful benefit in subjects with the reduction of lactose intolerance symptoms. We are now looking forward to commencing our Phase 3 program, following our end-of-Phase 2 meeting with the FDA to discuss the steps needed for an NDA submission," said Michael D. Step, Chief Executive Officer of Ritter Pharmaceuticals.Andrew J. Ritter, Co-Founder and President of Ritter Pharmaceuticals, added, "We look forward to advancing RP-G28 into Phase 3, taking us one step closer to developing the first FDA-approved treatment for lactose intolerance, a condition suffered by over 40 million in the U.S. and millions more worldwide."First Quarter 2017 Financial ResultsFor the first quarter of 2017, Ritter Pharmaceuticals reported a net loss attributable to common stockholders of approximately $1.7 million compared to a net loss of approximately $3.1 million for the first quarter of 2016. Basic and diluted net loss per share was $0.14 for the three months ended March 31, 2017 compared to basic and diluted net loss per share of $0.36 for the same period in 2016.Research and development expenses for the first quarter of 2017 totaled approximately $432,000 compared to approximately $1.9 million for the first quarter of 2016. This decrease was due to the completion of the Phase 2b/3 clinical trial.General and administrative expenses for the first quarter of 2017 and 2016 were approximately $1.2 million.As of March 31, 2017, Ritter Pharmaceuticals had cash and cash equivalents of approximately $5.1 million.About Ritter Pharmaceuticals Ritter Pharmaceuticals, Inc. (www.RitterPharma.com, @RitterPharma) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product candidate, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic, and liver disease.Forward-Looking StatementsThis release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to our ability to bring RP-G28 to market. Management believes that these forward-looking statements are reasonable as and when made. However, such statements involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the drug development process generally, including the outcomes of planned clinical trials and the regulatory review process. For a discussion of certain risks and uncertainties affecting Ritter Pharmaceuticals' forward-looking statements, please review the Company's reports filed with the Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Ritter Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.        RITTER PHARMACEUTICALS, INC.     CONDENSED STATEMENTS OF OPERATIONS     (Unaudited)               For the Three Months Ended  March 31,         2017     2016     Operating costs and expenses                     Research and development   $ 432,154     $ 1,882,848       Patent costs     77,702       32,364       General and administrative     1,171,325       1,235,018         Total operating costs and expenses     1,681,181       3,150,230                         Operating loss     (1,681,181 )     (3,150,230 )                       Other income                     Interest income     7,946       20,566       Other income     --       1,214         Total other income     7,946       21,780                                 Net loss   $ (1,673,235 )   $ (3,128,450 )                                           Net loss per share, basic and diluted   $ (0.14 )   $ (0.36 )                       Weighted average shares outstanding, basic and diluted     11,619,197       8,583,259                                                                  RITTER PHARMACEUTICALS, INC.     CONDENSED BALANCE SHEETS               March 31, 2017     December 31, 2016         (unaudited)           ASSETS                   Current assets                     Cash and cash equivalents   $ 5,092,309     $ 7,046,282       Prepaid expenses     149,727       156,752         Total current assets     5,242,036       7,203,034                         Other assets     10,326       10,326     Property and equipment, net     22,235       23,542         Total Assets   $ 5,274,597     $ 7,236,902                         LIABILITIES AND STOCKHOLDERS' EQUITY                   Current liabilities                     Accounts payable   $ 1,634,698     $ 1,896,368       Accrued expenses     900,762       1,222,735       Other liabilities     15,133       14,736         Total current liabilities     2,550,593       3,133,839                         Stockholders' equity                   Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2017 and December 31, 2016     --       --     Common stock, $0.001 par value; 25,000,000 shares authorized; 11,619,197 shares issued and outstanding as of March 31, 2017 and December 31, 2016     11,619       11,619     Additional paid-in capital     49,853,196       49,559,020     Accumulated deficit     (47,140,811 )     (45,467,576 )       Total stockholders' equity     2,724,004       4,103,063                             Total Liabilities and Stockholders' Equity   $ 5,274,597     $ 7,236,902    ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextVerizon soars on beat, Starbucks' big China deal, AstraZeneca sinks as drug trial disappointsYahoo FinanceEngineer Finds Pattern; Makes Millions in StocksMoney MorningSponsoredFJ Company's FJ40 is the Toyota Land Cruiser you really wantAutoblogShares in AstraZeneca dive as key cancer drug trial failsAssociated PressJeff Bezos’ brief stint as world’s richest human ends with Amazon’s second-quarter whiffTechCrunchDiscover it: 4.8 out of 5 avg. by 24K+ customersDiscover CardSponsoredPascal Soriot 'here today' after bad trial results wipe £10bn from AstraZeneca valueThe TelegraphTrump’s unwitting legacy could be universal health coverageYahoo FinanceSean Hannity responds to claim he ran up a $42,000 tab at Trump's hotel after flying in a 70-year-old lobster from MaineBusiness Insider"Women Need To Carry This Device With Them"Siren SongSponsoredU.S. economic growth picks up in second quarter, wages continue to lagReutersTwitter is only famous now because of President Trump: NYSE traderYahoo Finance VideoInvestors yawn as US economic growth rebounds in the second quarter; Amazon fallsYahoo FinanceZuckerberg Wife's Ambitious Secret Finally ExposedUNewz.MeSponsoredIs a Surprise Coming for Apple (AAPL) This Earnings Season?ZacksWall Street opens lower as Amazon weighs on tech stocksReutersU.S. Would 'Utterly Destroy' North Korea Military, Says Top Army OfficialRyan: Yes we could do what he said, but not before North korea Utterly destoryed Seoul killing hundreds of thousands. That's not even considering if they use a nuke.Join the Conversation1 / 5252








